Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
KRAS
Biotech
ASCO: RevMed confident in RAS leadership as rivals square up
RevMed is using ASCO as a chance to spotlight the full data from the phase 3 trial of daraxonrasib, which took the world by storm earlier this year.
Darren Incorvaia
May 31, 2026 8:00am
Kura posts data on drug designed to unleash KRAS inhibitors
May 26, 2026 10:09am
AbbVie dips into boiling RAS waters with $1.45B biobucks deal
Apr 28, 2026 10:01am
AACR: Revolution rolls on in pancreatic cancer as RAS wave rises
Apr 21, 2026 5:35pm
AstraZeneca fronts $100M for Jacobio's pan-KRAS inhibitor
Dec 22, 2025 4:31am
Chinese biotech helmed by AZ veteran reels in $108M series B
Dec 10, 2025 3:45am
